#1 Clinical Trials Search in Europe

Dexamethasone Dihydrogen Phosphate Disodium Ph. Eur.

This article examines the use of Dexamethasone Dihydrogen Phosphate Disodium Ph. Eur. in clinical trials for treating multiple myeloma, a type of blood cancer affecting plasma cells. The drug is being studied in combination with other medications as part of various treatment regimens for both newly diagnosed and relapsed/refractory multiple myeloma patients. These trials aim to evaluate the efficacy, safety, and potential benefits of including dexamethasone in multi-drug therapies for improving patient outcomes.

Table of Contents

What is DEXAMETHASONE DIHYDROGEN PHOSPHATE DISODIUM?

DEXAMETHASONE DIHYDROGEN PHOSPHATE DISODIUM is a synthetic corticosteroid medication. It is a form of dexamethasone, which is a potent anti-inflammatory and immunosuppressive drug[1]. This specific formulation is designed for injectable use, typically administered intravenously (into a vein) or intramuscularly (into a muscle).

What is it used for?

DEXAMETHASONE DIHYDROGEN PHOSPHATE DISODIUM is used to treat various conditions, including:

  • Multiple Myeloma: It is a key component in the treatment of multiple myeloma, a type of blood cancer affecting plasma cells[1][2].
  • Anti-inflammatory Effects: It helps reduce inflammation in various parts of the body.
  • Immunosuppression: It can suppress the immune system, which is useful in treating autoimmune conditions.
  • Edema Reduction: It helps reduce swelling associated with certain medical conditions.

How is it administered?

DEXAMETHASONE DIHYDROGEN PHOSPHATE DISODIUM is typically administered as a solution for injection. It can be given through different routes:

  • Intravenous (IV) Use: Injected directly into a vein[3].
  • Intramuscular (IM) Injection: Injected into a muscle.

The method of administration depends on the specific condition being treated and the patient’s overall health status.

Dosage Information

The dosage of DEXAMETHASONE DIHYDROGEN PHOSPHATE DISODIUM varies depending on the condition being treated and individual patient factors. However, some general dosage information from the available data includes:

  • Maximum daily dose: Up to 40 mg[2]
  • In some treatment regimens, doses of 8 mg may be used[3]

It’s crucial to note that dosage should always be determined by a healthcare professional based on the individual patient’s needs and response to treatment.

Potential Side Effects

As with all medications, DEXAMETHASONE DIHYDROGEN PHOSPHATE DISODIUM can cause side effects. Some potential side effects include:

  • Increased risk of infections
  • Changes in blood sugar levels
  • Mood changes or psychiatric effects
  • Gastrointestinal issues
  • Changes in appetite or weight
  • Fluid retention

It’s important to discuss potential side effects with your healthcare provider and report any unusual symptoms during treatment.

Precautions and Considerations

When using DEXAMETHASONE DIHYDROGEN PHOSPHATE DISODIUM, several precautions should be considered:

  • Pregnancy and Breastfeeding: Special considerations are needed for use during pregnancy or while breastfeeding[2].
  • Cardiovascular Risk: Patients with high cardiovascular risk may need careful monitoring[3].
  • Infections: Due to its immunosuppressive effects, it may increase the risk of infections[3].
  • Long-term Use: Prolonged use may have additional risks and should be monitored closely by a healthcare provider.

Ongoing Research

DEXAMETHASONE DIHYDROGEN PHOSPHATE DISODIUM is being studied in various clinical trials, particularly for its use in multiple myeloma treatment. Some ongoing research includes:

  • Combination therapy with other drugs like carfilzomib, lenalidomide, and elotuzumab for newly diagnosed multiple myeloma[3].
  • Its role in treatment regimens before and after autologous stem cell transplantation for multiple myeloma[3].
  • Use in maintenance therapy for multiple myeloma patients[2].

These studies aim to optimize treatment strategies and improve outcomes for patients with multiple myeloma and potentially other conditions.

Aspect Details
Drug Name Dexamethasone Dihydrogen Phosphate Disodium Ph. Eur.
Drug Class Corticosteroid
Conditions Studied Newly diagnosed multiple myeloma, Relapsed/Refractory multiple myeloma
Trial Phases Phase III
Combination Therapies Used with various drugs including carfilzomib, lenalidomide, elotuzumab, and others
Primary Endpoints Progression-free survival, Overall survival, Response rates, Minimal residual disease negativity
Secondary Endpoints Quality of life, Safety and tolerability, Long-term efficacy
Patient Population Adults (typically 18-70 years old) with multiple myeloma
Treatment Stages Induction, Consolidation, Maintenance, Salvage therapy
Dosing Varies by trial and combination therapy

FAQ

  • What is Dexamethasone Dihydrogen Phosphate Disodium Ph. Eur.? Dexamethasone Dihydrogen Phosphate Disodium Ph. Eur. is a form of dexamethasone, which is a corticosteroid medication. In these trials, it is being used as part of combination therapies to treat multiple myeloma, a type of blood cancer.
  • How is this drug being used in multiple myeloma clinical trials? The drug is being used in combination with other medications as part of various treatment regimens. It's included in therapies for both newly diagnosed multiple myeloma patients and those with relapsed or refractory disease.
  • What are the main goals of these clinical trials? The main goals include evaluating the effectiveness of treatment combinations including dexamethasone, assessing patient survival rates, measuring response to treatment, and monitoring the safety and side effects of the therapies.
  • Who can participate in these clinical trials? Eligibility varies by trial, but generally includes adult patients with multiple myeloma. Some trials focus on newly diagnosed patients, while others are for those with relapsed or refractory disease. Specific health criteria and prior treatment history also factor into eligibility.
  • What are some potential benefits and risks of participating in these trials? Potential benefits include access to new treatment combinations that may be more effective than standard therapies. Risks may include unexpected side effects or the possibility that the new treatment may not be as effective as hoped. All participants receive close medical monitoring throughout the trial.

Ongoing Clinical Trials on Dexamethasone Dihydrogen Phosphate Disodium Ph. Eur.

  • Comparison of allogeneic stem cell transplantation versus conventional therapy in patients with multiple myeloma who relapsed after first-line therapy

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Germany

  • Study on Alnuctamab and Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +8

  • Study on Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Germany

Glossary

  • Multiple Myeloma: A type of blood cancer that affects plasma cells, which are a type of white blood cell that normally produces antibodies to fight infections.
  • Relapsed Multiple Myeloma: When multiple myeloma returns after a period of remission or response to treatment.
  • Refractory Multiple Myeloma: When multiple myeloma does not respond to treatment or stops responding to treatment.
  • Autologous Stem Cell Transplant (ASCT): A procedure where a patient's own stem cells are collected, stored, and then returned to them after high-dose chemotherapy to help rebuild their immune system.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives without their cancer getting worse.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Minimal Residual Disease (MRD): A small number of cancer cells that remain in the body during or after treatment, which can only be detected by highly sensitive tests.
  • IMWG Criteria: International Myeloma Working Group criteria, which are standardized guidelines used to assess response to treatment in multiple myeloma.
  • Quality of Life (QoL): A measure of a person's overall well-being and ability to function in daily life, often assessed in cancer clinical trials.
  • Induction Therapy: The first phase of treatment for multiple myeloma, typically using a combination of drugs to reduce the amount of cancer in the body.
  • Consolidation Therapy: Additional treatment given after the main treatment to further reduce the number of cancer cells in the body.
  • Maintenance Therapy: Ongoing treatment given after the main treatment to help keep cancer from coming back.

References

  1. http://clinicaltrials.eu/trial/study-on-alnuctamab-and-drug-combination-for-patients-with-relapsed-or-refractory-multiple-myeloma/
  2. http://clinicaltrials.eu/trial/study-comparing-allogeneic-stem-cell-transplantation-and-lenalidomide-for-patients-with-relapsed-multiple-myeloma-after-first-line-therapy/
  3. http://clinicaltrials.eu/trial/study-on-elotuzumab-carfilzomib-lenalidomide-and-dexamethasone-for-patients-with-newly-diagnosed-multiple-myeloma/